HC Wainwright Estimates Alpha Cognition Q2 Earnings

Alpha Cognition Inc. (NASDAQ:ACOG) – Equities researchers at HC Wainwright issued their Q2 2027 earnings estimates for shares of Alpha Cognition in a research note issued on Wednesday, April 8th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.10) per share for the quarter. HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock.

Alpha Cognition (NASDAQ:ACOG) last issued its earnings results on Thursday, March 26th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The company had revenue of $2.60 million during the quarter, compared to the consensus estimate of $4.41 million. Alpha Cognition had a negative return on equity of 55.71% and a negative net margin of 202.23%.

Separately, Wall Street Zen downgraded shares of Alpha Cognition from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $18.00.

Alpha Cognition Stock Performance

NASDAQ ACOG opened at $6.38 on Thursday. The firm’s 50 day moving average price is $5.64 and its 200-day moving average price is $6.09. Alpha Cognition has a 52-week low of $3.97 and a 52-week high of $11.54. The company has a market cap of $138.89 million, a PE ratio of -5.50 and a beta of 2.51.

Hedge Funds Weigh In On Alpha Cognition

A number of hedge funds and other institutional investors have recently modified their holdings of ACOG. Green Alpha Advisors LLC bought a new position in shares of Alpha Cognition during the fourth quarter valued at approximately $72,000. Geode Capital Management LLC bought a new position in shares of Alpha Cognition during the second quarter valued at approximately $112,000. Massar Capital Management LP bought a new position in shares of Alpha Cognition during the second quarter valued at approximately $116,000. Berkshire Asset Management LLC PA boosted its stake in shares of Alpha Cognition by 50.7% during the third quarter. Berkshire Asset Management LLC PA now owns 17,824 shares of the company’s stock valued at $116,000 after purchasing an additional 6,000 shares in the last quarter. Finally, Zullo Investment Group Inc. bought a new position in shares of Alpha Cognition during the third quarter valued at approximately $127,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.